ASX News
Telix and Kanazawa University Cleared to Commence Prostate Cancer Imaging Study in Japan
Melbourne (Australia) and Kyoto (Japan) – 22nd February 2021. Telix Japan receives Clinical Trial Notification (CTN) clearance to commence a Phase I trial of its prostate cancer imaging product in Japan.
Telix is pleased to announce its subsidiary, Telix Pharmaceuticals Japan KK, in collaboration with Kanazawa University, has received Clinical Trial Notification (CTN) clearance by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) to commence a Phase I trial of its prostate cancer imaging product TLX591-CDx (Kit for the preparation of 68Ga-PSMA-11 injection) in Japan.
In December 2020, Telix Japan commenced a clinical collaboration with Kanazawa University to conduct a Phase I trial of TLX591-CDx enrolling 10 patients with advanced prostate cancer. The purpose of the trial is to obtain preliminary clinical data in a suitable patient population, confirming that the targeting and pharmacology of TLX591-CDx is equivalent to non-Japanese patients. Such clinical data will support future planning discussions with the objective of PMDA product approval in Japan, aligning with the marketing authorisations that Telix has already submitted in the US, EU, Canada and Australia.
Prof. Seigo Kinuya, Professor of Nuclear Medicine at the Kanazawa University Hospital, Department of Nuclear Medicine, Chair of the Japanese Society of Nuclear Medicine, and Chair of the National Conference for Nuclear Medicine Theranostics stated, “68Ga-PSMA-11 has been studied widely and intensively across the globe outside of Japan. Clinical data have been accumulated and its diagnostic efficacy and clinical application have been well characterised in guidelines in nuclear medicine and urology, worldwide. This first clinical trial of 68Ga-PSMA-11 prostate imaging in Japan is a crucial milestone to pave the way to provide state-of-the-art diagnostics to Japanese prostate cancer patients.”
Telix Pharmaceuticals Japan K.K. President Dr. Shintaro Nishimura added, “This study is the first formal clinical trial in Japan of a gallium 68-labeled PET imaging agent, which many Japanese nuclear medicine and urology physicians have been waiting for. We would like to express our appreciation to our pioneering colleagues at Kanazawa University’s Departments of Nuclear Medicine and Urology, the Innovative Clinical Research Center of Kanazawa University Hospital, the Kanazawa Advanced Medical Center, ATOX Co. Ltd and IRE ELiT (Belgium) for their exceptional support and collaboration in this project.”
To read the full ASX release please click here.
More Articles
ASX News
Telix Pharmaceuticals Releases Results for the Year Ended 31 December 2020 and 2020 Annual Report
Melbourne (Australia) – 26th February 2021. Telix Pharmaceuticals Limited Releases Full-Year 2020 Results and 2020 Annual Report.
ASX News
Telix and Kanazawa University Cleared to Commence Prostate Cancer Imaging Study in Japan
Melbourne (Australia) and Kyoto (Japan) – 22nd February 2021. Telix Japan receives Clinical Trial Notification (CTN) clearance to commence a...
ASX News
Telix FY2020 Results and Company Update Conference Call
Melbourne (Australia) – 16th February 2021. Telix to present the Company’s FY2020 results together with an update on Telix’s operations.
ASX News
Czech Republic Grants National Authorisation for the Use of Telix’s Prostate Cancer Imaging Product
Melbourne (Australia) and Liège (Belgium) – 16th February 2021. Telix announces the Ministry of Health of the Czech Republic is...
ASX News
Telix and Heidelberg University Hospital to Develop Next Generation Theranostics
Melbourne (Australia) and Heidelberg (Germany) – 10th February 2021. Telix announces research cooperation agreement with Heidelberg University Hospital to develop...
Corporate Spotlight
Industry Leaders’ Round-Table at SNMMI Mid-Winter Satellite Symposium
3rd February 2021 | Corporate Spotlight – Recording of Industry Leaders’ Round-Table Discussion at SNMMI Mid-Winter Symposium: Ga-68 PSMA-11: Advances...
ASX News
First U.S. Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 25th January 2021. Telix Pharmaceuticals announces the first U.S. patients have been dosed...
Corporate Spotlight
Telix Pharmaceuticals Appoints Danielle Meyrick MD as CMO, Asia-Pacific
22nd January 2021 – Corporate Spotlight | Telix Pharmaceuticals welcomes Dr Danielle Meyrick as Chief Medical Officer, Asia Pacific
Corporate Spotlight
ARTMS and Telix Pharmaceuticals Announce Successful Production of 68Ga PSMA-11 with Cyclotron Produced 68Ga from a Solid Target
Burnaby, Canada and Indianapolis, USA, January 12, 2021 – ARTMS Inc. and Telix announce successful production of Telix’s prostate cancer...
ASX News
Telix Pharmaceuticals Files New Drug Submission with Health Canada for Prostate Cancer Imaging Product
Melbourne (Australia) and Indianapolis, IN (USA) – 16th December 2020. Telix has filed a New Drug Submission (NDS) with Health Canada...
ASX News
Telix Pharmaceuticals and Mauna Kea Technologies Launch Urologic Oncology Alliance
Melbourne (Australia) – 16th December 2020. [Article updated with new video 16th February 2021] Telix Pharmaceuticals announces collaboration with Mauna...
ASX News
Telix and Kanazawa University Commence Japanese Clinical Study for Prostate Cancer Imaging
Melbourne (Australia) – 14th December 2020. Telix announces its subsidiary, Telix Pharmaceuticals Japan KK, has entered a clinical study collaboration...
ASX News
Telix Completes IP Agreement with the University of Southampton (UK) Granting Exclusive Access to TRALA Clinical Trial Data
Melbourne (Australia) – 14th December 2020. Telix Pharmaceuticals Limited announces today that its wholly-owned subsidiary TheraPharm GmbH has completed an...
ASX News
Telix Granted TGA Priority Review for Prostate Cancer Imaging
Melbourne (Australia) – 7th December 2020. Telix has been granted Priority Review status for TLX591-CDx (68Ga-PSMA-11), a radiopharmaceutical for the...
ASX News
Telix and DuChemBio Announce Korean Partnership for Advanced Prostate Cancer Imaging
Melbourne (Australia) and Seoul (South Korea) – 3rd December 2020. Telix Pharmaceuticals announces it has entered into a licensing and partnership...
ASX News
Telix Receives Approval for First-In-Human Study of Next Generation Prostate Cancer Therapy Product
Melbourne (Australia) – 2nd December 2020. Telix has been granted HREC approval and received CTN clearance by the TGA to...
ASX News
Investor Briefing – TheraPharm GmbH Acquisition
Melbourne (Australia) – 1st December 2020. Telix Pharmaceuticals Provides Investor Briefing: TheraPharm GmbH Acquisition
ASX News
Telix Pharmaceuticals Limited Acquires TheraPharm GmbH
Melbourne (Australia) and Baar (Switzerland) – 30th November 2020. Telix announces it has entered into an agreement with Scintec Diagnostics...
ASX News
Telix New Drug Application for Prostate Cancer Imaging Product Accepted by US FDA
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 24th November 2020. Telix Pharmaceuticals announces New Drug Application (NDA) for TLX591-CDx (Kit...